Related by context. All words. (Click for frequent words.) 78 erlotinib Tarceva ® 77 dasatinib Sprycel ® 77 CYT# potent vascular disrupting 77 GW# [003] 77 imatinib Gleevec ® 76 oral prodrug 76 Enzastaurin 76 orally administered inhibitor 76 multi kinase inhibitor 76 dasatinib Sprycel 76 selective modulator 76 MAGE A3 ASCI 76 liposomal formulation 76 thalidomide Thalomid 76 fosbretabulin 75 PNP inhibitor 75 ADP receptor antagonist 75 proteasome inhibitor 75 Xanafide 75 IAP inhibitor 75 sorafenib Nexavar 75 docetaxel Taxotere ® 75 PKC# 75 Sapacitabine 75 acyclovir Lauriad R 75 Kinase Inhibitor 75 gefitinib Iressa 75 Dasatinib 75 investigational humanized monoclonal antibody 75 CCR5 antagonist 75 peripherally acting 75 relapsed MM 75 PEGylated Fab fragment 75 Aplidin 75 vemurafenib 75 ENMD # 75 selective antagonist 75 nucleoside analog 75 YONDELIS 74 Aflibercept 74 dexamethasone Decadron 74 Talabostat 74 Amrubicin 74 Gleevec resistant 74 sunitinib malate 74 histone deacetylase HDAC inhibitor 74 highly selective inhibitor 74 cilengitide 74 bevacizumab Avastin ® 74 alvespimycin 74 pertuzumab 74 tyrosine kinase inhibitor 74 cetuximab Erbitux R 74 protein kinase inhibitor 74 5 HT2A inverse 74 Bosutinib 74 MGd 74 Blinatumomab 74 novel VDA molecule 74 regorafenib 74 PDE4 inhibitor 74 demonstrated antitumor activity 74 BRAF inhibitor 74 targeted radiotherapeutic 74 Pertuzumab 74 Ozarelix 74 hypereosinophilic syndrome 73 Annamycin 73 Vidofludimus 73 reversible inhibitor 73 Omacetaxine 73 LymphoStat B belimumab 73 protein tyrosine phosphatase 1B 73 microtubule inhibitor 73 advanced metastatic renal 73 Panzem R NCD 73 Epratuzumab 73 Peginterferon alfa 2b 73 vinca alkaloid 73 generation purine nucleoside 73 metastatic colorectal 73 AKT inhibitor 73 Deforolimus 73 PI3K/Akt pathway inhibitor 73 Dapagliflozin 73 non nucleoside inhibitor 73 Tarceva TM 73 immunomodulatory therapy 73 Cloretazine 73 Panzem NCD 73 Ceflatonin 73 Hsp# Inhibitor 73 Irinotecan 73 multikinase inhibitor 73 bortezomib Velcade 73 riociguat 73 Denufosol 73 sodium glucose cotransporter 73 Pazopanib 73 alefacept 73 galiximab 73 metaglidasen 73 Temsirolimus 73 alkylating agent 73 forodesine 73 Romidepsin 73 Bucindolol 73 ZACTIMA 73 denileukin diftitox 73 refractory NSCLC 73 Carfilzomib 73 mertansine 73 AEG# 73 nilotinib Tasigna ® 73 myelofibrosis polycythemia vera 73 Zorbtive TM 73 Vidaza azacitidine 73 HGS# 73 imatinib Gleevec 73 Aurora Kinase 73 HDAC Inhibitor 73 docetaxel Taxotere R 73 Pemetrexed 73 IL# PE#QQR 73 assessing T DM1 73 Tyrima 73 myelodysplastic myeloproliferative diseases 73 vascular disrupting agent 73 polycythemia vera essential thrombocythemia 73 EGFR TKI 73 Pathway Inhibitor 72 JAK inhibitor 72 cMET 72 AAG geldanamycin analog 72 paclitaxel Taxol 72 Factor VIIa 72 ara C 72 Pharmacokinetics PK 72 IMiDs ® compound 72 Orally administered 72 tumor xenograft models 72 Seliciclib 72 sunitinib Sutent 72 evaluating tivozanib 72 Granulocyte Colony Stimulating Factor 72 HCD# [002] 72 polymerase inhibitor 72 plasma kallikrein inhibitor 72 leukemia AML 72 humanised monoclonal antibody 72 novel histone deacetylase 72 Bezielle 72 multitargeted 72 mTOR inhibitors 72 nilotinib Tasigna 72 sunitinib Sutent ® 72 5alpha reductase 72 refractory chronic lymphocytic 72 beta 1a 72 alpha 2A 72 myeloproliferative diseases 72 IMA# 72 pregabalin Lyrica 72 Mycophenolate Mofetil 72 familial amyloidotic polyneuropathy FAP 72 huC# DM4 72 papillary renal cell carcinoma 72 Pafuramidine 72 tubulin inhibitor 72 Xeloda ® 72 biliary tract cancer 72 essential thrombocythemia ET 72 histone deacetylase inhibitor 72 trabectedin 72 visilizumab 72 stage IIIB 72 lapatinib Tykerb 72 pan HDAC inhibitor 72 miconazole Lauriad ® 72 Torisel 72 Archexin 72 FOLOTYN ® 72 Azacitidine 72 Anidulafungin 72 Personalized Immunotherapy 72 Methylnaltrexone 72 chimeric monoclonal antibody 72 lenalidomide Revlimid R 72 somatostatin analog 72 MKC# MT 72 Neulasta ® 72 polycythemia vera PV 72 recurrent glioblastoma multiforme 72 Phase #b/#a clinical 72 epithelial tumors 72 selective kinase inhibitor 72 Zolinza 72 CDK inhibitor 72 Degarelix 72 YONDELIS R 72 antibody MAb 72 Darinaparsin 72 basal cell carcinoma BCC 72 Akt inhibitor 72 Elagolix 72 kinase inhibitor 72 targeted antifolate 72 ZOLINZA 72 TLK# 72 virus HCV protease inhibitor 72 JAK inhibitors 72 orally bioavailable 72 tarenflurbil 72 cell lymphoma CTCL 71 kidney urologic 71 LHRH receptor positive 71 aripiprazole Abilify 71 superficial bladder cancer 71 sorafenib tablets 71 Cloretazine ® 71 Silodosin 71 brivanib 71 HSP# inhibitor 71 acetonide FA 71 Adjuvant Treatment 71 Nexavar sorafenib 71 T#I [002] 71 immunotherapeutic agent 71 CD# monoclonal antibody 71 FUSILEV enhances 71 mu opioid receptor antagonist 71 reslizumab 71 M2 subunit 71 formerly LymphoStat B 71 Squalamine 71 HDACi 71 Tasimelteon 71 castrate resistant prostate cancer 71 cisplatin gemcitabine 71 Angiotensin Converting Enzyme 71 small molecule tyrosine 71 chronic eosinophilic leukemia 71 cutaneous T 71 RhuDex ® 71 vinorelbine tartrate 71 mTOR inhibitor 71 Immunotherapeutic 71 Lubiprostone 71 PI3K inhibitor 71 phase IIb clinical 71 Teriflunomide 71 ZD# [001] 71 hormone LHRH antagonist 71 Mg Usa 71 signal transduction inhibitor 71 Pralatrexate 71 ganetespib 71 HuLuc# 71 EGFR HER2 71 Fludara ® 71 SPRYCEL ® 71 BAL# [002] 71 Safinamide 71 immune modulating 71 vinca alkaloids 71 Meets Primary Endpoint 71 metastatic renal cell carcinoma 71 metastatic malignant 71 OMP #R# 71 HGS ETR2 71 relapsing remitting MS RRMS 71 TNF Tumor Necrosis Factor 71 Bortezomib 71 IMiDs R 71 selective orally bioavailable 71 Maribavir 71 Janus Kinase 71 ixabepilone 71 Daclizumab 71 adalimumab Humira 71 OMP #M# 71 thetreatment 71 Onconase 71 gemcitabine Gemzar 71 Phase 2b Clinical Trial 71 IGF IR 71 phase Ib 71 panitumumab Vectibix 71 SUTENT ® 71 intravesical instillation 71 FLT3 71 XL# XL# 71 Evoltra ® 71 IMiDs ® 71 oral rivaroxaban 71 mTOR mammalian target 71 elotuzumab 71 Panzem R 71 CCX# 71 monoclonal antibody conjugated 71 antisense inhibitors 71 Kinoid 71 weekly subcutaneous injections 71 cetuximab Erbitux ® 71 Clolar ® 71 fluoropyrimidine 71 phase IIb trial 71 IgG1 monoclonal antibody 71 bevacizumab Avastin R 71 anti angiogenic agent 71 selective estrogen receptor modulator 71 highly selective endothelin 71 Epidermal Growth Factor Receptor 71 liposomal doxorubicin 71 erlotinib Tarceva 71 cediranib 71 bendamustine 71 Pivotal Phase III 71 #D#C# 71 Cutaneous T 71 LHRH antagonists 71 selectively inhibited 71 Traficet EN 71 Ganciclovir 71 pomalidomide 71 ritonavir boosted 71 OMNARIS HFA 71 angiogenesis inhibitor 71 2 methoxyestradiol 71 Vimpat R 71 antiangiogenesis 71 MEK inhibitor 71 Granted Orphan Drug 71 volociximab 71 Myelodysplastic Syndrome MDS 71 docetaxel Taxotere 71 VEGF inhibitors 71 HER2 positive metastatic breast 71 PEGylated anti 71 Diffuse Large B 71 Tyrosine Kinase Inhibitor 71 Dacogen decitabine 70 Vaprisol 70 aurora kinase 70 Exherin TM 70 IAP inhibitors 70 vidofludimus 70 Mitoxantrone 70 IMC A# 70 posaconazole 70 R Saizen R 70 SERMs 70 rALLy clinical trial 70 anthracycline taxane 70 humanized anti 70 GSK# [001] 70 mapatumumab 70 MEK inhibitors 70 BMS # 70 oropharyngeal candidiasis OPC 70 mRCC 70 TO AVOID PREGNANCY WHILE 70 radiation sensitizer 70 intranasal formulation 70 Vidaza R 70 selective phosphodiesterase 70 interleukin IL -# 70 including eniluracil ADH 70 MKC# MKC# PP 70 JAK2 inhibitor 70 gamma secretase inhibitor 70 Fulvestrant 70 BRIM2 70 humanized monoclonal antibody 70 estramustine 70 BAY #-# 70 paclitaxel poliglumex 70 Phase Ib II 70 CCR9 antagonist 70 myeloproliferative disorders 70 Quinamed 70 mycophenolate mofetil 70 etanercept Enbrel 70 unique alkylating agent 70 selectively inhibits 70 Fludarabine 70 pathophysiological effects 70 vascular disrupting agents 70 idarubicin 70 Factor Receptor 70 xenograft models 70 PEG IFN 70 Kit CD# positive 70 hypoxia activated prodrug 70 UPLYSO 70 M# rationally 70 ospemifene 70 Certolizumab pegol 70 Velcade bortezomib 70 NS5b 70 lymphoid malignancies 70 vapreotide acetate 70 gastrointestinal stromal tumors GIST 70 Preclinical studies suggest 70 flutamide 70 ceftazidime 70 receptor blocker 70 Cloretazine R 70 GMX# 70 potent antiproliferative 70 tyrosine kinase inhibitors TKIs 70 HCV NS5B polymerase 70 Nilotinib 70 Vorinostat 70 basiliximab 70 gemcitabine Gemzar ® 70 humanized monoclonal 70 Troxatyl 70 HQK 70 TRO# 70 indinavir Crixivan 70 BENLYSTA ® 70 Tigecycline 70 ALK inhibitors 70 multiple myeloma MM 70 receptor inhibitor 70 Fingolimod 70 Initiate Phase 70 erythropoietic 70 nucleoside analogues 70 CYP#A# CYP#D# 70 Phase 1b clinical trials 70 nucleoside reverse transcriptase inhibitor 70 Pegloticase 70 Luteinizing Hormone Releasing Hormone 70 Aurora kinase inhibitor 70 Gleevec Glivec 70 Aliskiren 70 SinuNase TM 70 Interferon alpha 70 Noxafil 70 VAPRISOL 70 refractory CTCL 70 CTAP# Capsules 70 Vidaza ® 70 5 fluorouracil leucovorin 70 cathepsin K inhibitor 70 Melphalan 70 TBC# 70 pegfilgrastim 70 fluoroquinolone antibiotic 70 calcineurin inhibitor 70 kinase inhibition 70 Enzyme Replacement Therapy 70 factor TNF 70 Lenalidomide 70 MCSP respectively 70 agent VDA 70 Apaziquone 70 5 FU leucovorin 70 Elotuzumab 70 SAR# [004] 70 PEGylated interferon 70 Simulect 70 EGFR inhibitors 70 Afatinib 70 Soft Tissue Sarcoma 70 investigational therapies 70 HuMax EGFr 70 INCB# [003] 70 Completes Patient Enrollment 70 Proxinium TM 70 SYN# 70 Interferon beta 70 class mGluR5 inhibitor 70 CYP#A# substrate 70 OncoVex 70 Allovectin 7 70 refractory metastatic 70 Nexavar ® 70 Anthracycline 70 Triapine 70 TLR9 agonist 70 mitoxantrone plus 70 amrubicin 70 ATL# [001] 70 non thiazolidinedione TZD 70 Bevacizumab 70 5 HT6 receptor 70 TLR8 agonist 70 initiated Phase Ib 70 trastuzumab DM1 T DM1 70 small molecule thrombopoietin 70 Lenocta 70 Eculizumab 70 anticancer compound 70 systemic RNAi therapeutic 70 GRN# 70 proteasome inhibitors 70 lintuzumab SGN 70 small molecule Hedgehog 70 SCCHN 70 taxane chemotherapy 70 TELINTRA 70 trastuzumab Herceptin R 69 MDS AML 69 nucleotide analogue 69 R sorafenib tablets 69 Clofarabine 69 KSP inhibitor 69 SNT MC# 69 systemically administered 69 Mipomersen 69 afamelanotide 69 prostate cancer HRPC 69 PI3K/mTOR 69 gemcitabine carboplatin 69 candidates Azedra TM 69 triciribine phosphate monohydrate 69 Xelox 69 selective inhibitor 69 depsipeptide 69 histamine dihydrochloride 69 CYC# 69 metastatic RCC 69 Nanobody 69 acadesine 69 pediatric Crohn disease 69 Microplasmin 69 systemic anaplastic large 69 Phase Ib clinical 69 Eraxis 69 PRT# 69 lexidronam injection 69 agonistic human 69 BCR ABL inhibitors 69 rilonacept 69 CEQ# 69 taxane resistant 69 Anti VEGF 69 VEGF inhibitor 69 TMC# [002] 69 dyskinesia PD LID 69 immunomodulator 69 GRASPA ® 69 adriamycin 69 Voreloxin 69 VNP#M 69 docetaxel chemotherapy 69 histone deacetylase HDAC 69 Aviptadil 69 Initiates Phase II 69 Dabigatran etexilate 69 signal transduction inhibitors 69 Myocet 69 Tumor Necrosis Factor 69 lanreotide 69 Herceptin trastuzumab 69 Gleevec imatinib mesylate 69 HMG CoA reductase inhibitors 69 HuMax CD4 69 relapsed refractory multiple myeloma 69 RhuDex TM 69 R lenalidomide 69 Sudhir Agrawal D.Phil 69 Ceflatonin R 69 Laquinimod 69 oral dual endothelin 69 direct thrombin inhibitors 69 TKI therapy 69 gastrointestinal stromal tumors GISTs 69 alfa 2a 69 oral antiviral 69 enzastaurin 69 Yondelis ® 69 Initiates Enrollment 69 echinocandin 69 cyclin dependent kinase inhibitor 69 tipifarnib 69 novel oral anticoagulant 69 tiuxetan 69 Estrogen Receptor 69 bevacizumab Avastin 69 nucleoside analogs 69 Mg Uk 69 oral Janus kinase 69 albiglutide 69 Bicalutamide 69 tigecycline 69 Hedgehog Pathway Inhibitor 69 hyaluronidase enzyme 69 alpha folate receptor 69 inhibitor RG# 69 BRAF mutant 69 irreversible inhibitor 69 DNA intercalator 69 tumors GIST 69 Darunavir 69 Solazed 69 Aclidinium 69 Advanced Renal Cell 69 anti angiogenic agents 69 tyrosine kinase inhibitor TKI 69 PSN# [002] 69 VEGFR2 inhibitor 69 Vascular Disrupting Agent 69 receptor modulators 69 Arranon 69 teriflunomide 69 cytokine refractory 69 DU #b 69 efalizumab 69 MT#/MEDI-# 69 Crizotinib 69 PEG SN# 69 Tesetaxel 69 itraconazole Sporanox 69 HERCEPTIN 69 FOLFOX6 chemotherapy regimen 69 Aplidin R 69 Initiates Clinical 69 subependymal giant cell 69 #I TM# 69 HCV protease inhibitors 69 Cytochrome P# 69 Camptosar ® 69 hormone refractory metastatic prostate 69 5 HT3 receptor 69 ErbB2 positive 69 neratinib 69 IMiDs 69 Achieves Primary Endpoint 69 multicenter Phase II 69 GV# [001] 69 dihydrochloride 69 Nitazoxanide 69 LymphoStat B TM 69 Aptivus ® 69 Patients Treated With 69 NS#/#A protease 69 goserelin 69 Albuferon TM 69 Everolimus 69 talabostat 69 budesonide foam 69 Rituxan rituximab 69 investigational monoclonal antibody 69 Golimumab 69 somatostatin analogue 69 tyrosine kinase inhibitors 69 metastatic hormone refractory 69 MabCampath 69 Romiplostim 69 VEGF receptor inhibitor 69 LEUKINE 69 proliferator activated receptor 69 BENICAR HCT 69 Serostim ® 69 Cethromycin 69 insulin sensitizers 69 tumor necrosis 69 p# inhibitor 69 Ofatumumab 69 Ambrisentan 69 Olaparib 69 ribavirin RBV 69 K ras mutations 69 TRAIL receptor antibodies 69 AVASTIN 69 evaluating T DM1 69 Dalbavancin 69 oral nucleoside analogue 69 INSPIRE Trial Phase III 69 JAK2 inhibitors 69 Paraplatin ® 69 DEB# 69 molecular imaging radiopharmaceutical 69 CCR5 inhibitor 69 androgen receptor antagonist 69 dexpramipexole 69 TNF alpha selectively neutralizing 69 Pimavanserin 69 Neoadjuvant 69 Eltrombopag 69 samalizumab 69 Nexavar tablets 69 dirucotide MBP# 69 Atrasentan 69 Complicated Skin 69 potently inhibited 69 NS5B polymerase 69 Doxil ® 69 antineoplastic 69 TroVax ® 69 mGluR5 NAM 69 ocular formulation 69 AQ4N 69 ketolide antibiotic 69 EGFR tyrosine kinase inhibitors 69 non nucleoside 69 ACTEMRA TM 69 thiazolides 69 Atypical Hemolytic Uremic Syndrome 69 Belimumab 69 APTIVUS r 69 Triapine R 69 5 Fluorouracil 69 Epirubicin 69 Gemcitabine 69 haloperidol Haldol 69 Trastuzumab DM1 69 paclitaxel cisplatin 69 Curaxin CBLC# 69 AZT zidovudine Retrovir 69 ergot derivatives 69 unresectable stage 69 benign prostatic hypertrophy BPH 69 recurrent glioblastoma 69 gastrointestinal stromal tumor GIST 69 trastuzumab Herceptin ® 69 Tanespimycin 69 clobazam 69 epigenetic therapies 69 HGS ETR1 69 Alzhemed TM 69 diarrhea predominant irritable 69 TKB# 69 TAFA# 69 Combination REOLYSIN R 69 chemopreventive agent 69 E1 INT TM 69 Trandolapril 69 Raptiva ® 69 severe gastroparesis 69 OXi# 69 HGS ETR1 mapatumumab 69 androgen independent 68 PDX pralatrexate 68 Antitumor 68 Ridaforolimus 68 antiangiogenic agent 68 stated Michelle Berrey 68 Ophena TM 68 developing Bicifadine serotonin 68 ELACYT 68 alpha 2b 68 Fluconazole 68 CD# CEA 68 alpha blocker 68 Omnitarg 68 EVIZON TM 68 SCH # 68 triggers apoptosis programmed 68 cyclophosphamide methotrexate 68 preclinically 68 Sprycel dasatinib 68 delta gamma agonist 68 colorectal carcinoma 68 immunomodulating 68 Initiates Clinical Trial 68 mGluR5 negative 68 sorafenib Nexavar R 68 receptor antagonists 68 olaparib 68 eribulin mesylate 68 fallopian tube cancers 68 Omacetaxine mepesuccinate 68 EOquin 68 Liposomal 68 huN# DM1 68 gastrointestinal stromal tumors 68 oral ghrelin agonist 68 Receives Orphan Drug Designation 68 GTC recombinant human 68 Onco TCS 68 rituximab Rituxan 68 alpha 2A adrenergic 68 Vicinium TM 68 ALGRX 68 Vandetanib 68 small molecule glucokinase 68 Refractory Hodgkin Lymphoma 68 CG# [003] 68 LHRH antagonist 68 Gleevec imatinib 68 EGFR TKIs 68 Phase IIb Trial 68 ALN TTR 68 Solazed TM 68 mTOR kinase 68 diabetic gastroparesis 68 luteinizing hormone releasing 68 Aurora kinase 68 Sym# 68 nucleoside analogue 68 intravesical infusion therapy 68 Hepatocellular Carcinoma HCC 68 Spiegelmer ® 68 immune modulators 68 ® lenalidomide 68 targeting CD# 68 humanized therapeutic 68 DFMO 68 PGL# 68 Roflumilast 68 Presents Preclinical Data 68 APTIVUS 68 oral dihydropyrimidine dehydrogenase DPD 68 omacetaxine mepesuccinate 68 CHOP chemotherapy 68 3TC lamivudine Epivir 68 Trabectedin 68 BCR ABL inhibitor 68 BENLYSTA TM 68 Zarnestra 68 canakinumab 68 Capesaris 68 metastatic HRPC 68 Glioblastoma Multiforme 68 Sutent sunitinib 68 diagnostic biomarker 68 blinded randomized placebo controlled 68 refractory metastatic colorectal cancer 68 Successfully Completes Phase 68 Neupogen ® 68 Symadex 68 5 HT3 antagonist 68 adefovir dipivoxil 68 imatinib resistant 68 PrevOnco 68 aurora kinase inhibitor 68 Gefitinib 68 Ranolazine 68 HER2 overexpression 68 quetiapine Seroquel 68 anti EGFR antibody 68 RANK Ligand inhibitor 68 PPAR gamma agonist 68 epothilones 68 Metastatic Melanoma 68 iobenguane 68 Certican 68 either acutely decompensated 68 mGluR2 NAM 68 corticosteroid dexamethasone 68 TEMODAL 68 Naive Patients 68 PANVAC VF 68 Plicera 68 Phase III Clinical Trial 68 Initiate Clinical Trial 68 flavopiridol 68 ALK inhibitor 68 poly ADP ribose polymerase 68 isoform selective 68 Allovectin 7 ® 68 Cardiotoxicity 68 biologic DMARD 68 Delafloxacin 68 peripherally restricted 68 metastatic bladder 68 abacavir Ziagen 68 CCR1 68 topoisomerase II inhibitor 68 JAK1 68 humanized antibody 68 selective immunoproteasome inhibitor 68 Onalta ™ 68 NS5A 68 Isavuconazole 68 Initiates Phase III 68 selective androgen receptor modulator 68 Calcitonin 68 humanised antibody 68 sorafenib Nexavar ® 68 rufinamide 68 XL# anticancer compounds 68 bortezomib Velcade R 68 BCG refractory carcinoma 68 CD4 monoclonal antibody 68 Posaconazole 68 TG# [003] 68 Janus kinase 68 VELCADE melphalan 68 glucagon receptor 68 mda 7 68 5 HT4 receptor 68 Cannabinor 68 pan histone deacetylase 68 relapsed leukemia 68 phase IIa clinical 68 Tocilizumab 68 EGFR tyrosine kinase inhibitor 68 SAR# [002] 68 metastatic malignant melanoma 68 GVAX ® 68 immune modulator 68 Targretin capsules 68 FOLFOX6 68 pediatric acute lymphoblastic 68 generation Hsp# inhibitor 68 Pegylated 68 caspofungin 68 Alfacell proprietary ribonuclease 68 Taxotere docetaxel 68 immunosuppressant drug 68 Darusentan 68 Capecitabine 68 CLORETAZINE TM VNP#M 68 AEGR 68 dosage regimens 68 cyclophosphamide chemotherapy 68 piperacillin tazobactam 68 hypomethylating agents 68 generation antisense inhibitor 68 elacytarabine 68 investigational protease inhibitor 68 Genasense ® 68 Alkeran 68 Hormone Refractory Prostate Cancer 68 Sorafenib 68 Navelbine ® 68 fluticasone furoate 68 lenalidomide dexamethasone 68 recurrent NSCLC 68 nucleotide analogs 68 topical ophthalmic 68 PD LID 68 biologic therapy 68 leukotriene receptor antagonist 68 Investigational Oral 68 CIMZIA ™ 68 benzimidazole 68 Ziprasidone 68 Catena ® 68 multicenter Phase III 68 lipoglycopeptide 68 NMDA antagonist 68 octreotide implant 68 motesanib 68 Ribavirin causes 68 reversible inhibitors 68 HCV polymerase 68 ovarian carcinoma 68 Decitabine 68 plus prednisone prednisolone 68 topically administered 68 LHRH agonists 68 dopamine D2 68 accumulate preferentially 68 dextromethorphan quinidine 68 Xyfid TM 68 c MET 68 Marqibo TM 68 Cetrorelix 68 immunomodulatory properties 68 tanespimycin 68 SUTENT 68 PXD# 68 NOX E# 68 THR beta agonist 68 idiopathic thrombocytopenic purpura ITP 68 #HT#A 68 metabotropic glutamate receptors 68 Neulasta R 68 nonnucleoside reverse transcriptase inhibitors 68 Intravenous CP 68 Pagoclone 68 sarcoma melanoma 68 ® bortezomib 68 BCG refractory 68 antibody MT# 68 atypical Hemolytic Uremic Syndrome 68 neuroendocrine cancers 68 PRN FDA Approves 68 Plaquenil 68 mRNA antagonist 68 Prolongs Survival 68 Daptomycin 68 haematological malignancies 68 p# MAP kinase inhibitor 68 cytostatic 68 metastatic neuroendocrine tumors 68 imatinib mesylate 68 Investigational Treatment 68 ARIKACE ™ 68 Mirapexin 68 Etoposide 68 trastuzumab DM1 68 letrozole Femara 68 potent CYP#A# inhibitors 68 pegylated liposomal doxorubicin 68 gemtuzumab ozogamicin 68 metastatic GIST 68 ALN HPN 68 EGFr 68 small molecule chemotherapeutic 68 Interferon gamma 68 topical gel formulation